Report Date: 2026-11-16 | Subject: International Credit Ratings (industry slug: international-credit-ratings) | Industry View: Cautiously Bullish (next 12 months, medium confidence)
This report is organized around financial archetypes, with headline focus on "Profitability · Franchise Asset Quality · Capital Returns" (I4) and "Licenses & Market Share" (I5): credit rating is a regulatorily mandated information infrastructure business—the balance sheet is not the product; licenses, regulatory citations, and reputational capital are the assets. Its cycle is driven by the debt issuance cycle, and its return quality is determined by oligopoly pricing power. The core conclusion up front: this is a duopoly franchise business with roughly 40% of revenue annuitized, operating margins above 60%, and a regulatory-citation moat that ceded only 5.4 percentage points over 17 years. However, since 3Q26 the key variables for the next 12 months are: the issuance cycle decelerating from cyclical highs, unit fee rates being diluted by large refinancing deals, and the regulatory reshaping of private ratings—the cycle direction still points up; return realization depends on valuation and timing.
Subject: The services industry that issues credit opinions on global bonds and debt instruments. The core layer consists of the three major international agencies—S&P Global Ratings (a segment of listed S&P Global/SPGI), Moody's Ratings (Moody's Ratings/MIS, a segment of Moody's Corporation/MCO), and Fitch Ratings (wholly owned by Hearst, unlisted). The second layer comprises regional/niche agencies—DBRS Morningstar (owned by Morningstar, the fourth largest in the EU), KBRA (a pioneer in private credit ratings), AM Best (a niche monopolist in insurance financial strength ratings), and Japan's JCR/R&I duopoly. The third layer consists of China's domestic licensed agencies (14 firms including China Chengxin International, United Credit Ratings, Dagong Global, Golden Credit Rating, and China Chengxin Pengyuan, plus investor-pays CCXI).
Business Model: The issuer-pays model accounts for roughly 86% (per Moody's disclosure). Revenue = transactional initial rating fees (tied to issuance size, on a tiered decreasing scale plus complexity premiums) + non-transactional annual surveillance fees/entity annual fees (annuity-like). Adjacent layers: ratings data subscriptions (Moody's Analytics, ARR of approximately USD 3.7 billion) and private letter ratings (not publicly disclosed).
Scope Exclusions: Personal credit bureaus, ESG ratings (a separate regulatory track), and pure internal model vendors. One-sentence industry chain map: issuers (pay for ratings) → rating agencies (research + rating committee + publication) → investors (regulatory capital, investment mandates, index inclusion cite ratings—free-riding but forming network effects).
Rating demand = debt issuance activity × rating reliance. Global long-term fixed income issuance in 2025 was USD 29.9 trillion (+6.3%, a record; SIFMA 2026 Capital Markets Fact Book), of which the US accounted for USD 11.5 trillion (+9.7%: corporate bonds USD 2.2 trillion, +12.5%; ABS USD 517.4 billion, +33.3%; municipals USD 587.3 billion, +14.3%). 2024-2025 confirmed a strong recovery from the high-rate trough of 2022-2023: Moody's rated issuance rose +42% in 2024 (leveraged loans +118%, high yield +80%, structured finance +57%) and +8% in 2025. But 2026 has already shown deceleration from highs and structural divergence—in 3Q26 Moody's rated issuance fell -2%, HY issuance -21% (revenue -40%), leveraged loan issuance -35% (revenue -27%), while IG revenue rose +18% (driven by AI/hyperscale data center financing, per company disclosure attribution).
The fee pool structure by rating category (on Moody's MIS 2025 rating revenue of USD 4.084 billion): Corporate Finance (CFG) 52.2%, Financial Institutions (FIG) 18.6%, Public/Project/Infrastructure Finance (PPIF) 15.5% (2025 +13%, on surging data center and infrastructure IG financing), Structured Finance (SFG) 13.7% (issuance +57% in 2024 and +22% in 2025—the asset class with the highest rating density). By market: the US represents 38.5% of global issuance; European government bond issuance hit a record EUR 415.8 billion in fiscal 2025 (AFME); East Asia's emerging-market local currency bond stock was USD 28.6 trillion (June 2025, ADB), with a four-year CAGR of approximately 7.9%, and Big Three coverage remains low—making it a penetration growth pole.
Regulatory citations form a demand floor partially decoupled from issuance volumes. The US "investment grade" definition still effectively anchors on ratings (investment policies, indices, internal controls); the Basel standardized approach's external ratings (ECRA/ECAI) remain the primary anchor for global bank capital measurement; and EU Solvency II's CQS 0-6 tiers map directly to external ratings. Dodd-Frank §939 (2010) "removal of regulatory references" has largely been implemented (SEC money market fund Rule 2a-7 switched to definitions of eligible short-term securities, etc.); the net effect is a decline in direct statutory citations but retention of definitional reliance; academic research shows structural decline in demand for the third rating (Fitch) after §939 (University of Sydney study). China went further: the 2021 five-ministry notice "returned the lead in rating demand to the market," removed mandatory ratings at issuance, and weakened pledged repo reliance, compounded by removing external rating requirements for insurance investments (CBIRC Office Circular [2021] No. 118)—a precedent-setting experiment in "regulatory de-reliance" globally (see I6 for details).
Counter-evidence on investor acceptance is the history of rating failures: structured products in 2008, and Silicon Valley Bank in 2023 (Moody's downgraded it just one notch to Baa1—still investment grade—days before collapse). Yet after each failure, regulatory and market reliance on the Big Three did not collapse; demand follows an "event shock-repair" pattern.
Per S&P Global Ratings: global maturities of its rated corporate bonds (including loans/revolvers) for 2025-2029 total USD 12.35 trillion, with USD 262.4 billion in 2026, USD 250.9 billion in 2027, and USD 278.3 billion in 2028 (five-year high); 2026-2028 totals USD 7.92 trillion, averaging USD 263.9 billion per year, 27.2% higher than 2025. US maturities for 2026-2028 are USD 382.9 billion, with non-financial speculative grade rising steeply from USD 25.4 billion in 2026 to USD 68.2 billion in 2028. HY issuers typically refinance 12-18 months ahead (BNY), meaning the 2027-2028 maturity peak pulls issuance forward into 2026 and H1 2027. Watch for front-loaded exhaustion: BNY judges that 2026 is the peak refinancing year—part of the record 2025 issuance was early absorption of 2026 maturities rather than net incremental demand over the next 12 months; Fitch data shows the leveraged loan maturity wall does not steepen until 2028.
Base year 2025 global long-term fixed income issuance of USD 29.9 trillion → 2028E of approximately USD 34.35 trillion (CAGR 4.7%): trend growth of 3.5%/year contributes +USD 3.25 trillion; above-trend drivers total roughly +USD 1.20 trillion per year—maturity wall rollover +USD 0.60 trillion/year (S&P maturity schedule × 70% public market rollover rate + HY front-loading), IG net issuance from rate cuts × AI capex +USD 0.30 trillion/year, private credit securitization revival +USD 0.35 trillion/year (US ABS +43.3% in 2024, +33.3% in 2025), emerging market penetration +USD 0.15 trillion/year, China's regulatory de-reliance -USD 0.20 trillion/year. Cross-checked against top-down (extrapolating Moody's/S&P guidance and SIFMA's mid-range growth of 5.5%/year → USD 35.1 trillion), the deviation is -2.2%—cross-validation passes. Inflection point qualification: AI financing's boost to IG revenue (3Q26 +18%) has hard data, but the "AI share of IG" and "per-unit usage multiples" links lack public quantification, so this is a potential (not yet quantified) inflection point, not a headline assertion.
The compliant supplier pool is tiny and tiered: US NRSRO registrations stood at 11 after January 2026 (Peru's PCR newly added; SEC 2025 Staff Report on NRSROs); EU ESMA registrations 19 (16 with <10% share); China's dual-registration system 14 firms. But "registration" and "being cited" are two different things: the Big Three hold 93.38% of US outstanding rated securities (end-2024; 98.8% in 2007—ceding only 5.4 percentage points over 17 years, with cessions concentrated in ABS/government categories going to KBRA/DBRS); EU rating and ancillary services revenue CR3 = 91.87% (ESMA 2025 edition: S&P 50.42%, Moody's 29.63%, Fitch 11.82%). NRSRO registration legally requires applicants to provide written proof that Qualified Institutional Buyers (QIBs) have used their ratings for at least three years—making "market acceptance" a precondition for entry—and the SEC is legally prohibited from evaluating methodology quality (registration is not an endorsement).
A quantified ramp-up case: DBRS was founded in 1976 and only gained SEC certification for regulatory use after 27 years; once recognized, one notch was worth about 39bp of capital cost (Kisgen & Strahan, NBER); after Morningstar's USD 669 million acquisition in 2019, its EU revenue share remains only 1.99%—49 years of history plus a cash acquisition still leaves it in the "mid-tier." KBRA, founded in 2010, was sold in 2021 at a valuation of roughly USD 900 million (at the time 400+ employees and 51,000 ratings); by 2026 it has 700+ employees and 65,000 ratings—15 years to reach the second tier, still not the large tier. AM Best's niche monopoly in insurance financial strength ratings (covering roughly 3,500 insurers in 90 countries, with NAIC citations creating institutional demand) proves a niche can be defended but is hard to extend. Conclusion: regulatory recognition (registration) is a fast variable (years), while monetization is a slow variable (decade-scale); the Big Three's cross-cycle default coverage history is the only non-replicable asset.
Moody's MIS had 6,128 employees in 2025 (1,556 US + 4,572 non-US), compensation expense of USD 1.136 billion (27.6% of revenue), and revenue per employee of roughly USD 670,000; S&P Global's capex/revenue was only 1.27% (USD 195 million in 2025). A single rating = 2-3 analysts for several weeks plus committee review; surveillance fees have near-zero marginal cost—capacity expansion relies almost purely on incremental headcount, buildable in 6-18 months. The real bottlenecks are "credentialed talent" (conflict-of-interest segregation, non-compete/recusal constraints) and demand-side lock-in from fund mandates/indices naming the Big Three.
Supply Conclusion: Registration poses no supply shortage; the supply of "cited ratings" is highly constrained. Expansion is easy, monetization extremely hard; substitution erosion concentrates on the structured/private side (estimated to have diverted 15-25% of the industry's incremental revenue elasticity—estimation basis), while corporate bond/sovereign core pools are impenetrable by all three substitution routes (AI/internal ratings/Chinese domestic) to regulatory citations.
The industry's nominal average fee is roughly 3.5bp (Big Three + DBRS revenue pool of USD 10.49 billion ÷ global long-term fixed income issuance of USD 29.9 trillion; the nominal basis includes non-rated fee-exempt treasuries, so the fee-charging basis is higher). Fee spectrum (calculated from certainty instruments): a USD 45 million US municipal issue paying S&P + Moody's a combined USD 31,700 = 7.04bp (combined for the two, roughly 3.5bp each); China's self-regulatory pact floor (debt ≥ CNY 150k / per issue ≥ CNY 250k / surveillance ≥ CNY 50k) equates to roughly 1.7-5bp; large IG refinancings at roughly 0.3-1bp (size-decreasing); complex structured deals higher. Pricing power has three layers of origin: oligopoly structure + regulatory citation lock-in (buyers have no bargaining exit); the convention of annual fee schedule increases (roughly 2-3% built into contracts); and complexity premiums. The EU requires per-client fee disclosure to ESMA, and fee differences must be explainable by cost differences only (transparency, not price caps); China's pact is an anti-price-war floor, not downward pricing pressure. Issuer-pays is roughly 86% (investor-pays is only CCXI, positioned as a public good and difficult to scale).
A caution on volume-price decomposition: In Q4-25, S&P transactional revenue grew +12% vs. billed issuance +28%, implying unit fee of -13.0%; in 3Q26, +1% vs. +8%, again implying -6.5%—beneath the apparent stickiness of "fee schedules never cyclically cut," the combination of large low-fee refinancings and AI jumbo bonds is already diluting realized unit fees by 6-13% per year. This is genuine erosion beneath the surface of rising volumes and stable prices, requiring continuous tracking of the growth gap between billed issuance and transactional revenue.
FY2025: S&P ratings segment revenue USD 4.724 billion (+8%, transactional USD 2.470 billion / non-transactional USD 2.254 billion), adjusted operating profit USD 3.079 billion (+12%), margin 65.2% (+218bps); Moody's MIS revenue USD 4.119 billion (+9%), margin 63.6% (+350bps). In 3Q26 margins already showed pullback: MIS 64.4% (-80bps YoY), S&P ratings 65.7% (-130bps)—a high-level deceleration signal. Margin drivers = operating leverage (revenue +8% vs. expenses +4-5%) + AI efficiency gains compressing labor per unit output + mix effects; if issuance returns to normal growth rates, the margin range is judged at 63-66%, biased toward the lower end (the assumption of 65%+1pp at the upper end has already been pierced by current-quarter data).
Capital returns: Moody's ROE of 64.5% (2025) is mainly propped up by 73.4% leverage and USD 2-3 billion of annual buybacks—it cannot serve as evidence of business quality. On a deleveraged basis, ratings segment ROIC is roughly 17-20% (estimate). Asset-light verification: SPGI capex/revenue of 1.27%, Moody's normally ~4.4%, FCF conversion >60% (MIS free cash flow of USD 2.2 billion, +22% in the first three quarters of 2026). Growth investment is people + brand, with short payback periods—in essence, franchise returns rather than capital-intensive returns.
Revenue structure checks (calculated from certainty data): S&P FY2025 non-transactional share 47.7%; Moody's MIS 2024 transactional share 66% (per S&P research), 3Q26 recurring revenue share 34.3%—on a revenue-weighted basis the two companies' true annuity cushion is roughly 41-44% (44.1% if Moody's recurring is taken at the 40% cap), with transactional at roughly 56-59%. Trough measurement: from the 2021 peak to the 2023 trough, MIS revenue fell to USD 2.860 billion (roughly -14% from peak) while issuance nearly halved over the same period—the annuity cushion + fee stickiness provided roughly 3x buffering; from the 2023 trough to 2025, +44.0%, against issuance +53%—a blended revenue elasticity of roughly 0.83, with volume beta of roughly 0.57-0.6 after stripping annual fee increases. Qualitative conclusion: this is neither a pure annuity subscription business nor a pure cyclical beta business, but a hybrid of "an annuity-like franchise base (~40%, growing 8-10%/year and not declining even at troughs) + the debt issuance cycle as elasticity (~60%, volume beta 0.6-0.8)"—bull-market elasticity is diluted, bear-market downside is floored, but 3Q26's negative elasticity of -27% to -40% on the leveraged side proves the downside protection is a cushion, not immunity.
Pricing framework = issuance (CAGR 4.7-5.5%) × rating penetration × fee schedule (stickiness + mix dilution of -6 to -13%) + annuity cushion (~40%, +8-10%). Calendar-year path: 2026E Big Three + DBRS pool of roughly USD 11.25 billion (+7.2%, anchored to Moody's high-single-digit guidance [reaffirmed 2026-10-21] and S&P's +6-8% organic guidance) → 2027E of roughly USD 11.93 billion (+6%). On a quarterly rhythm, 4Q26-1Q27 is the seasonal peak (Q4 billed issuance catch-up + annual fee recognition, supported by the USD 262.4 billion 2026 maturity wall), with 3Q27 the seasonal trough. Scenarios (next 12 months TTM growth, Big Three + DBRS pool): Bear +0-3% (roughly USD 10.5-10.8 billion), Base +4-7% (roughly USD 10.9-11.2 billion), Bull +9-12% (roughly USD 11.4-11.8 billion)—the base case takes the lower end of the guidance path rather than the midpoint, reflecting 3Q26 deceleration and the constraints of maturity-wall front-loaded exhaustion.
No major reputational impairment in the current period: following SVB/First Republic, no material liability recovery proceedings against the Big Three were found; the US Rule 436(g) amendment has long been in limbo (rating agencies are not generally treated as "experts" under securities law); EU Article 35a civil liability has few successful precedents; and Article 40 of China's Measures for the Administration of Information Disclosure for Corporate Credit Bonds—joint and several liability with a reversed burden of proof—is a liability premium unique to the Chinese sub-market. Tail scenarios must be explicitly disclosed: if an SVB-style failure of investment-grade ratings recurs, the US and Europe could replicate China's 2021-style "return of rating-demand dominance to the market"—a regulatory repricing of the business model (probability below 5%, with a one-time impact of -10% to -20% industry beta); the 95bp premium of private ratings and the jump in defaults are triggering scrutiny from the FSB (its 2026-05 report named "rating inflation reports" and "authorities' inability to verify subscription services") and ESMA (call for evidence, 2026-04)—if regulators restrict private/subscription ratings, what shrinks is the high-margin incremental pool, not merely a headwind for small agencies.
EU revenue basis (ESMA 2025 edition): S&P 50.42% (+2.61pp), Moody's 29.63% (-0.96pp), Fitch 11.82%, DBRS 1.99%, Scope 1.23% (shrinking from 1.83%), KBRA 0.97%; CR3=91.87%, CR5 ~95.1%—Article 8d (dual ratings must consider agencies with ≤10% share) has failed to shake the landscape after years of implementation, and Scope, the intended beneficiary of support provisions, has in fact been shrinking. US outstanding-volume basis: the Big Three at 93.38%, government securities locked at 98.6%, with mid-sized agencies holding share only in ABS/CLO niches. China mandate-volume basis: CR3=67% (2026Q1, +3pp QoQ); concentration is rising under "supporting the strong and restricting the weak"; the top three by market-based evaluation are CCXI, United Credit Ratings, etc.; foreign player S&P China ranks 6th and Fitch Bohua 4th.
(Metric caveat: this chart shows the EU revenue-basis CR3=91.87%; the 93.38% US figure above is the outstanding-ratings-count basis, and China's 67% is the mandate-volume basis. The three metrics measure different objects and are not directly comparable; citations throughout this report are individually labeled accordingly.)
Profits sit almost entirely in the "Big Three issuer-pays rating" segment: adjusted segment operating margins of 63.6-65.2%, far above the rest of their parent companies' businesses (Moody's Analytics 33.1%); the global issuer-pays rating fee pool is roughly USD 12.7-13.6 billion per year (estimated by back-solving from the two Big Three disclosed revenues of USD 8.86 billion, or 65-70% of the global total; Fitch is characterized by parent Hearst as its "single largest source of profit"). Three profit migration lines (next 2-3 years): ① Private credit ratings—Moody's private-credit-related transactions +70%, with 2026 guidance of 750-850 first-time mandates; second-tier agencies issued over 6,000 private letter ratings in 2023 (roughly three-quarters of share, FT)—fastest-growing but with the largest regulatory uncertainty; ② Structured finance revival—securitization issuance +57% in 2024 / +22% in 2025, favoring SF-strong agencies; ③ One-off rating fees → subscription data—Moody's Analytics ARR of USD 3.7 billion (+8%, retention 95%); Fitch Solutions accounts for over 20% of Fitch's revenue. The conceding parties: Chinese domestic agencies (rate wars + ratings reduced to compliance attachments) and squeezed-out small agencies (Scope). Share × market reconciliation: S&P USD 4.72 billion + Moody's USD 4.12 billion + Fitch estimated ~USD 1.65 billion + DBRS USD 0.35 billion + others ~USD 0.8-1.2 billion + China ~USD 0.5-0.6 billion ≈ USD 12.6-13.7 billion, consistent with the back-solved pool, with no order-of-magnitude discrepancy.
Bargaining power upstream and downstream: crushing power over issuers (issuers are highly fragmented, and no rating = surging funding costs; one rating notch ≈ 39bp of capital cost vs. rating fees of 3.5bp—issuers' extreme price insensitivity is the root of pricing power); rating shopping is the only countermeasure and of limited effect (China 2025Q3: 219 agencies switched, with only an 8.68% post-switch upgrade rate); investors free-ride broadly (yet investors' eligible-agency lists are precisely the source of network effects); regulators apply sustained pressure but have not touched the issuer-pays foundation. Return quality conclusion: this business, taken as a whole, is one of the highest-quality franchises in all of finance—60%+ margins, roughly 40% annuity-like, asset-light, with self-reinforcing network effects; the "real money" is in the Big Three's core pools; second-tier niches (SF/insurance/private credit) are truly growing but with an obvious size ceiling; the China domestic segment is a sample of prosperity illusion—revenue growth without profit growth.
| Institution | Position/share | Key metrics | One-line read |
|---|---|---|---|
| S&P Global Ratings (SPGI) | EU revenue leader at 50.42% and rising | FY2025 revenue USD 4.724 billion, margin 65.2%, non-transactional 47.7% | Industry price-setter: index + ratings dual franchise, strongest cyclicality resistance |
| Moody's Ratings (MCO) | EU 29.63%, second | FY2025 revenue USD 4.119 billion, margin 63.6% (+350bps) | The other half of the duopoly: greatest SF/private credit elasticity, but also the largest leveraged finance exposure |
| Fitch (unlisted) | EU 11.82%, third | Revenue undisclosed (Hearst private), estimated ~USD 1.65 billion | The gap to third place is entrenched; no standalone listed exposure |
| DBRS/Morningstar (MORN) | EU 1.99%, fourth | 2025 revenue ~USD 354 million (+21.7%) | Best-positioned second-tier: Art.8d compliance option + SF depth; ceiling is scale |
| KBRA (unlisted) | EU 0.97% | 700+ employees, 65,000 cumulative ratings | Private credit pioneer: highest growth; regulation and default tests cut both ways |
| AM Best | #1 in insurance FS rating niche | Covers ~3,500 insurers in 90 countries | Textbook niche monopoly; slow lane |
| China Chengxin International (CCXI) | China mandate top tier (within CR3) | 312 analysts; unlisted, financials undisclosed | Most likely winner of China's industry consolidation, but profit model awaits reshaping |
| United Credit Ratings | China top tier | 323 analysts (most in industry) | Capacity/turnover player; best able to spread costs in a rate war |
| JCR / R&I | Japan domestic duopoly | Japan share unavailable | Living sample of a regional franchise: comfortable but non-exportable |
A-shares have no Shenwan sub-industry for credit ratings; industry-level A-share valuation percentile unavailable; substituted with the two listed US parents (caveat: both include non-rating segments): SPGI closed at USD 473.59 on 2026-11-13, ~24.3x FY2026 guidance EPS (USD 19.40-19.65), ~23.5-28x TTM GAAP (metric differences); MCO hit a low of USD 455.65 after its 3Q26 earnings miss, ~28-30x FY2026 adjusted guidance EPS (USD 16.40-17.00) (~37x FY2025 GAAP basis). 10-year valuation percentiles for both stocks unavailable (overseas data feeds unreachable this session; stale aggregator percentiles not cited). Interpretation: the historical valuation band for the rating franchise is 25-35x, and the current level sits at the band's midpoint rather than an extreme—SPGI underperformed sharply in 2026 on the "AI disrupting ratings and data" narrative (Morningstar 2026-03 deemed it 22% below its USD 570 fair value), and the divergence itself indicates the market has partially priced in deceleration; if rating revenue growth slips to 0-3%, compression from 28-35x to 22-25x is the main source of drawdown—this is prosperity rising × valuation midpoint, not prosperity rising × extreme overvaluation, nor × 20th-percentile undervaluation.
US: Dodd-Frank §939A dereferencing largely implemented (state insurance regulator NAIC still relies heavily on ratings; only RMBS/CMBS switched to model-based methods)—the demand floor declines slowly rather than collapsing; Rule 436(g) expert liability amendment in limbo, no major recoveries post-SVB—liability contained; NRSRO registration club stable at 10-11 agencies; 2025 annual reviews found issues at 9/10 agencies but no major new rules—entry barriers protect incumbents. EU: CRA Regulation + ESMA direct registration is the world's strictest framework; Art.8c/8d rotation and share rules nominally support small agencies, yet CR3 remains 91.87%; ESMA's call for evidence on private/subscription ratings (published 2026-04-16) is currently the most important regulatory variable; post-Brexit FCA regulates independently, and the EU equivalence list excludes the UK—cross-border supply is being jurisdictionalized. China: the 2019 Interim Measures for the Administration of the Credit Rating Industry unified filing requirements; the 2021 triple hit—“removal of mandatory ratings + weakened reliance on ratings for repo + insurance dropping external ratings"—was the world's first institutional precedent of de-regulatory-dependence, shifting the domestic demand floor down; on rates, bans on low pricing and rating-level competition (CSRC Order No. 181 + self-regulatory pact) amount in effect to price protection; Article 40 joint and several liability (reversed burden of proof) raises the liability premium of the Chinese sub-market; foreign access has landed (S&P China registered in 2019, the only wholly foreign-owned player with full licenses) but share remains more symbolic than real. Geopolitics: March 2022 sanctions on Russia led the Big Three to fully exit Russia (revenue to zero + the "weaponization of ratings" narrative); Moody's downgrade of US Treasuries to Aa1 on 2025-05-16 triggered no regulatory retaliation but heated up the politicization of sovereign ratings; BRICS/domestic alternative rating agencies are "strong on narrative, weak on execution" (no operational BRICS rating agency found).
Net direction (four dimensions): demand floor 0 (slow decline persists) / entry barriers +1 (strengthening) / rates 0 (transparency offset by China's price protection) / liability 0 (contained in US/EU, tightening in China) → total ~+1, neutral-to-positive for Big Three incumbents; structural headwinds concentrate in Chinese domestic agencies and sanctioned markets.
| Scenario | Probability | Rating revenue | Narrative and implications |
|---|---|---|---|
| Bear | 30% | +0~3% (~USD 10.5-10.8 billion) | Leveraged finance slump through 2027 (HY/leveraged issuance -20~35% YoY) + AI capex deceleration + ESMA tightening the incremental pool via private rating action; margins 62-64%; high valuation × decelerating growth, rating stocks compress to 22-25x |
| Base | 50% | +4~7% (~USD 10.9-11.2 billion) | Maturity wall rolling (USD 2.64 trillion annual average 2026-28) + AI-IG and securitization staying strong + annuity cushion +8~10%; fee mix dilution of -6~-13% offset by volume and annual fee increases; margins 63-66%; valuation midpoint holds |
| Bull | 20% | +9~12% (~USD 11.4-11.8 billion) | Rate cuts accelerate HY/leveraged rebound (2024-style +42% repeat) + private credit securitization beats + jumbo issuance lifting unit fees; margins challenge the 66-67% upper bound |
| Date/window | Event | Directional impact | Debate |
|---|---|---|---|
| 2026-12 | Big Three/DBRS full-year outlook, 4Q26 billed issuance | Validates seasonal backfill and guidance achievement | D1 |
| 2027-01 | SPGI FY2026 results + 2027 guidance | Transactional revenue growth and unit fee dilution | D1 |
| 2027-02 | MCO FY2026 results + 2027 guidance; China quarterly mandate report | Leveraged finance exposure validation; China rates | D1/D3 |
| 2027-04 | SEC "2026 OCR Annual NRSRO Report" | Pace of share loosening | D2 |
| H1 2027 | ESMA call-for-evidence conclusions on private/subscription ratings | If restricted → high-margin incremental pool shrinks | D2 (high risk) |
| H1 2027 | HY advance refinancing window (2027-28 maturity wall) | Key test of maturity wall realization | D1 (high risk) |
| 2027-06 | ESMA CRA market share report, 2026 edition | EU CR3 and Scope shrinkage tracking | D2 |
| Ongoing | KBRA private credit default quarterly data, NAIC due diligence framework | Regulatory catalyst for private rating inflation | D2 |
Debunking the value-trap logic: bullish on the cycle ≠ worth buying. The "AI/quant rating providers" in the lower-right quadrant are the classic trap—high demand heat on the AI substitution narrative (right on the horizontal axis), but no NRSRO regulatory referencing path and no monetization (low on the vertical axis), with the Transparency Analytics withdrawal as precedent; KBRA and DBRS growth is real (+21.7% in 2025) but the size ceiling and the private-rating regulatory double-edged sword make returns below average. Chinese domestic ratings and Scope in the lower left are "Avoid"—not a prosperity illusion but actual downward prosperity (China de-dependence + Scope share shrinking 1.83%→1.23%) compounded by a damaged profit model. The upper-right duopoly is the core allocation zone, but return realization is sensitive to entry valuation (currently 24-30x forward, at the historical band midpoint; compression risk in the deceleration scenario).
Beneficiaries:
Avoid:
(Separate profiles can be created for SPGI/MCO etc. to obtain target prices and valuation details.)
| Scenario | Biggest beneficiaries | Biggest losers | Why |
|---|---|---|---|
| Bear (30%) | AM Best (insurance niche weakly correlated with issuance); CCXI (protected by domestic policy floor + consolidation winner) | MCO (largest leveraged/SF exposure + valuation compression); KBRA (private default test + regulatory tightening) | Collapse in transactional revenue hits leveraged finance exposure directly |
| Base (50%) | SPGI (annuity + guidance certainty); MCO (SF/private elasticity delivered) | Scope; Chinese domestic second-tier (pool not growing) | In moderate growth, share and margins determine returns |
| Bull (20%) | MCO (largest HY/leveraged rebound elasticity); MORN/DBRS (second-tier SF beta) | AM Best (relative underperformance, no cyclical elasticity) | High-beta segments rally first |
① Faster-than-expected decline in the bond issuance cycle (sustained -20~35% in HY/leveraged issuance, with the maturity wall confirmed as having been pulled forward); ② Regulatory reshaping of private ratings (ESMA/FSB restrictions on private/subscription-based ratings, shrinking the high-margin incremental pool); ③ Tail risk from rating failure events (a recurrence of an SVB-style investment-grade failure, triggering US/EU replication of China-style deregulatory reliance, a one-time -10~-20% sector shock); ④ Valuation compression (28-35x × slowing growth → 22-25x); ⑤ Politicization of sovereign ratings and escalating sanctions (spread of the "ratings weaponization" narrative). Falsification checklist (ongoing monitoring): two consecutive quarters of negative growth in SPGI/MCO ratings revenue; transaction revenue growth persistently trailing billed issuance by ≥5pp (refuting fee-rate stickiness); ESMA proposing private ratings restrictions; KBRA-basis private-label default rates >6.5% with spillover into BDC/CLO; HY/leveraged issuance down more than -25% YoY again in H1 2027 — any single trigger warrants a re-examination of this view.
Key Sources: SEC "2025 Staff Report on NRSROs"; ESMA "CRA Market Share Report 2025"; SIFMA "2026 Capital Markets Fact Book"; S&P Global 4Q/FY2025 earnings; Moody's 3Q26 earnings and FY2025 10-K; S&P Global Ratings "Global Corporate Debt Maturities Through 2029"; FSB "Report on Vulnerabilities in Private Credit" (2026-05); the 2021 notice jointly issued by the People's Bank of China and four other ministries; Kisgen & Strahan (NBER w14890); AFME European government bond reports; ADB "Asia Bond Monitor".
This report is industry research and does not constitute a recommendation to buy or sell any security. Markets carry risk; invest with caution.